SCHEMBL5035841

SCHEMBL5035841

CCOC(=O)c1cnc(Nc2ccc(Cl)cc2)s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 2/20 0.56
MAPK12 P53778 2/20 0.56
MAPK11 Q15759 2/20 0.56
MAPK14 Q16539 2/20 0.56
DHODH Q02127 2/20 0.56
MAPT P10636 6/20 0.55
RAB9A P51151 4/20 0.55
NPC1 O15118 3/20 0.55
SMN1; SMN2 Q16637 4/20 0.54
P2RX3 P56373 4/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 2/20 0.50
GAA P10253 1/20 0.50
HPGD P15428 1/20 0.50
HTT P42858 1/20 0.50
KDM4E B2RXH2 3/20 0.49
CDC7 O00311 1/20 0.49
DBF4 Q9UBU7 1/20 0.49
ALK Q9UM73 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL525917 0.85 RAB9A (0.50) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL10235581 0.84 DHODH (0.58) DHODHMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL5034834 0.82 MAPT (0.54) DHODHMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL23334316 0.80 DHODH (0.56) MAPK13MAPK12MAPK11MAPK14DHODH
SCHEMBL3629901 0.79 RAB9A (0.68) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL12291072 0.78 CDC7 (0.55) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL8345238 0.77 CDC7 (0.75) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL5035180 0.77 DHODH (0.61) DHODHMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL27937477 0.77 AURKA (0.44) MAPK13MAPK12MAPK11MAPK14DHODH
SCHEMBL31374355 0.76 CDC7 (0.54) MAPTRAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP disclosed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP disclosed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US disclosed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153962-A1 Thiazole derivatives CNR1, CNR2, GPR119 MAPK13 3031/4885MAPK12 2755/4885MAPK11 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.